TB-500 (Thymosin β4 fragment)

TB-500 in the Published Research

UKPWritten & reviewed by William Heath · Editor, UK Peptides research library2 min readLast reviewed 2026-08-233 cited sources

The short answer

Most of the literature is indexed under thymosin beta-4 rather than TB-500, because TB-500 is a supplier-facing development code rather than a term used in research papers. Searching only for TB-500 misses nearly all of it.

Key facts

Primary search term
Thymosin beta-4
Also useful
Tβ4, beta-thymosins, LKKTETQ
TB-500 in PubMed
Rare (it is a trade-side code)
Key review
Hannappel, Ann N Y Acad Sci 2007
Foundational
Low, PNAS 1981
Evidence type
Predominantly preclinical

Why searching for TB-500 fails

TB-500 is a development code that became a product name. Researchers publishing on the molecule write about thymosin beta-4 or its fragments, and index terms follow the science rather than the market. Anyone searching PubMed for TB-500 will find very little and may conclude the literature is thin, when in fact it is substantial under a different name.

What to search instead

Thymosin beta-4 is the primary term. Beta-thymosins covers the wider family. LKKTETQ finds work specifically on the motif, which is the closest match to the fragment itself. Searching all three gives a fair picture, and comparing what each returns is itself informative about how much work concerns the protein versus the peptide.

Research material referenced

TB-500 5mg, third-party HPLC tested

Buy TB-500 · £23.99

The two anchors

Low and colleagues' 1981 PNAS paper established the complete bovine sequence. Hannappel's 2007 review in the Annals of the New York Academy of Sciences covers the beta-thymosin family and is the sensible orientation point for anyone new to the area. Goldstein's 2012 review in Expert Opinion on Biological Therapy covers the regenerative literature.

The question to ask of every paper

Which molecule was administered. Full-length thymosin beta-4 and the LKKTETQ heptapeptide are both in the literature, and papers state which. Given that the commercially interesting findings and the fragment-attributable findings are largely different sets, this single check does more to clarify the evidence than any other.

What the shape of the literature tells you

Decades of work, concentrated in cell biology and preclinical models, with limited human clinical data and no established registered trial programme for the heptapeptide. That is a mature basic-science literature rather than a therapeutic development programme, and reading it as the latter overstates where it has got to.

Frequently asked questions

Why does PubMed return so little for TB-500?

It is a development and trade code rather than a term used in research papers. The literature is indexed under thymosin beta-4.

Which paper is the best starting point?

Hannappel's 2007 review in the Annals of the New York Academy of Sciences for orientation; Low 1981 in PNAS for the foundation.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Browse the wider literature

Live database searches, not fixed citations. Results change as new work is indexed.

UKP

Written and reviewed by

William Heath · Editor, UK Peptides research library

William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.

More TB-500 (Thymosin β4 fragment) articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.